Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Why it could be worth taking a look at Infratil (ASX:IFT) shares

Shares in investment company Infratil Ltd (ASX: IFT) have risen over 11% this month on the back of multiple expansion plans.

Infratil is a New Zealand-based company that you can think of like a publicly traded private equity company. It invests in its portfolio of assets and often sells them, hopefully at a much more attractive price.

Source: Rask Media IFT 2-year share price chart

Healthcare and renewable energy assets make up a large portion of its portfolio. It has assets in hydropower stations, wind farms, solar and diagnostic imaging services, just to name a few.

Infratil’s recent acquisition

Earlier this week, Infratil told the market it plans to acquire a majority stake in Auckland Radiology – another diagnostic imaging service with 32 radiologists and 15 clinics around the greater Auckland region.

As part of the transaction, Infratil will hold at least a 50.1% stake in the combined platform and will contribute between $30 million and $60 million.

Pacific Radiology will also hold a stake in the three-way partnership – another New Zealand-based diagnostic imaging service that Infratil purchased a controlling stake in for $350 million earlier this year.

On the recent acquisition, Infratil CEO Jason Boyes said that “Inorganic growth was a key pillar of the investment thesis for Infratil’s acquisition of Pacific Radiology, and we are pleased to see that thesis demonstrated early on in our ownership journey with the addition of an outstanding practice like Auckland Radiology.

Pre-synergies, the acquisition is return accretive to the Pacific Radiology investment case.”

My take on Infratil

This acquisition demonstrates the clear direction Infratil is heading by building out its investments in the healthcare space.

It now means Infratil has three diagnostic imaging services in its arsenal, with the third being Qscan – a service with over 300 machines predominantly across the eastern seaboard of Australia. I like these assets for two primary reasons. The first is that imaging services are often paid for by the public health system, resulting in reliable cash flows back to Infratil.

But the second is that there’s been a shift towards early diagnosis and preventative care, which bodes well for companies like Infratil that are involved with diagnostic imaging.

I’m also interested in Infratil’s stake in CDC data centers given the structural tailwinds that are likely to benefit this industry in years to come.

For some more share ideas, click here to read: 2 ASX small cap shares I’d buy in October.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report — or get it emailed to you — for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content